India's Suven Life Sciences Limited has received two product patents in Eurasia for new chemical entities, used in the treatment of disorders associated with Neurodegenerative diseases. These patents are valid till 2023.

The patents are valid in all contracting countries like Armenia, Azerbaijan, Belarus, Kyrgyzstan, Kazakhstan, Moldova, Russia, Tajikistan and Turkmenistan.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-degenarative disorders like Attention deficient hyperactivity, Alzheimer's, Parkinson, Schizophrenia and Huntington's.

Earlier this month, company has signed a second agreement with Eli Lilly & Co. to collaborate on the pre-clinical research of molecules in the therapeutic area of central nervous system disorders.